Deal Tracker · Therapeutic areas
Consumer health deals
3 Consumer health deals tracked by EPT across MENA & GCC — distribution, licensing & M&A. Most active: Hikma Pharmaceuticals, Dr. Reddy's Laboratories, Ramo Pharm & Rem3dy Health. Latest: Rem3dy Health → Hikma Pharmaceuticals (Distribution, 29 Oct 2026).
- Rem3dy Health → Hikma PharmaceuticalsDistribution · GCC · Undisclosed · 29 Oct 2026
- Sothema → Ramo PharmM&A / Acquisition · MENA · $6m · 28 Oct 2026
- Dr. Reddy's Laboratories → Hikma PharmaceuticalsLicensing · MENA · 28 Sept 2026
Browse deals
By region
MENA (53) · GCC (48) · Africa (14) · CIS & Central Asia (10) · Southeast Asia (8) · Global (LMICs) (5) · Türkiye (4) · Global ex-US (1)
By deal type
Licensing (38) · Distribution (25) · Technology transfer / Localization (23) · Partnership / Collaboration (22) · M&A / Acquisition (16) · Equity / Investment (7) · Joint venture (5) · Supply / Manufacturing (5)
By company
ADCAN Pharma (11) · Mubadala Bio (8) · Hikma Pharmaceuticals (6) · Jamjoom Pharma (6) · Bio-Thera Solutions (5) · Avalon Pharma (4) · SPIMACO (4) · Groupe Saidal (4) · Department of Health – Abu Dhabi (3) · Roche (3) · Sanofi (3) · Taiba Healthcare (3) · Tabuk Pharmaceuticals (3) · Dar Al Dawa (3) · Kazakhstan Ministry of Health (3) · Galenicum (2) · DKSH (2) · Laprophan (2) · Adalvo (2) · Eva Pharma (2) · Rameda (2) · Menarini (2) · AstraZeneca (2) · MS Pharma (2) · LifePharma (2) · JCR Pharmaceuticals (2) · Gen İlaç (2) · Philex Pharmaceuticals (2) · Lotus Pharmaceutical (2) · Elpen (2) · Dhofar Pharmaceutical Industries (2) · CCL Pharmaceuticals (2) · Abdi İbrahim (2) · Nordic Pharma (2) · SaudiVax (2) · Novo Nordisk (2) · VACSERA (2) · Lifera (2) · Julphar (2)
By therapeutic area
Multi-therapy (34) · Oncology (19) · Metabolic / Diabetes (18) · Cardiovascular (13) · Vaccines (11) · Immunology / Inflammation (8) · Ophthalmology (4) · Rare / Orphan (4) · CNS / Neurology (3) · Infectious Disease (3) · Respiratory (2) · Women's Health (2)